Kafrelsheikh University
Mohamed G. zeinhom, MD
Investigators aim to compare the effect of valproate versus propranolol in migraine by assessing the absolute reduction in MMD in each group and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency.
Migraine Disorders
Valproic Acid 500 MG
Propranolol
PHASE4
Investigators will enrol 600 migraine patients who are diagnosed according to ICHD3-beta criteria in our study and will use a questionnaire to detect their demographic and clinical features (disease duration, attack frequency, and duration, pain intensity assessed by the visual analogic scale and we have two groups the first group will include 300 patients and will receive 500-1000 mg valproate daily, and the second group will receive propranolol 160 mg per day. Investigators will assess The number of migraine days after three months of treatment and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 600 participants |
| Masking : | DOUBLE |
| Masking Description : | An independent statistician generated a blocked randomization sequence using computer-generated random numbers; participants received either lacosamide or propranolol from a specially trained and qualified nurse. We prepared Sequentially numbered opaque sealed envelopes and 600 labels for each drug labelled Drug A or B. According to the randomization chart, put them into envelopes numbered 1 to 600. Envelopes were attached to the patient's files. Patients were recruited sequentially and were given enrollment numbers starting from 1, which were mentioned in their files. Files with the same number as the patient enrolment number were opened, and the patients were assigned to receive drugs A or B. Drug A included valproate, and Drug B included propranolol. The statistical analysis was performed by an independent statistician who did not know the treatment protocol of groups A or B. |
| Primary Purpose : | TREATMENT |
| Official Title : | Valproate Versus Propranolol in Migraine, a Randomized Controlled Trial |
| Actual Study Start Date : | 2023-01-23 |
| Estimated Primary Completion Date : | 2024-07-01 |
| Estimated Study Completion Date : | 2024-07-05 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 18 Years to 75 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
RECRUITING
Kafr Elsheikh University Hospital
Kafr Ash Shaikh, Egypt, 33511